Related Experiment Video

Updated: Oct 13, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K

Antibiotic Therapies for Clostridioides difficile Infection in Children

Anne J Gonzales-Luna1, Travis J Carlson2, Kevin W Garey1

  • 1Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 4849 Calhoun Road, Houston, Texas, 77204, USA.

Journal of the Pediatric Infectious Diseases Society
|November 18, 2021
PubMed

Insights

Current Clostridioides difficile infection (CDI) treatment guidelines for children are outdated. Recent studies suggest fidaxomicin and vancomycin are more effective than metronidazole for pediatric CDI.

Area of Science:

  • Pediatric Infectious Diseases
  • Antimicrobial Stewardship

Background:

  • Pediatric Clostridioides difficile infection (CDI) rates are rising.
  • Current treatment guidelines for pediatric CDI lack robust evidence, relying on adult data and limited pediatric studies.
  • Existing guidelines recommend metronidazole or vancomycin for pediatric CDI.

Purpose of the Study:

  • To evaluate the efficacy of current and emerging treatments for pediatric Clostridioides difficile infection.
  • To provide evidence-based recommendations for pediatric CDI treatment.

Main Methods:

  • Review of existing pediatric CDI treatment guidelines.
  • Analysis of a recent randomized controlled trial (RCT) on pediatric CDI treatment.
  • Evaluation of recent observational studies comparing vancomycin and metronidazole in children.

Main Results:

  • The first pediatric CDI treatment RCT showed fidaxomicin non-inferior to vancomycin.
  • Observational data suggest vancomycin has higher clinical improvement rates than metronidazole for non-severe pediatric CDI.
  • Metronidazole may be less effective than vancomycin in hospitalized children with non-severe CDI.

Conclusions:

  • Fidaxomicin and vancomycin represent more appropriate, evidence-based treatment options for pediatric CDI compared to metronidazole.
  • Updated guidelines should consider recent evidence favoring fidaxomicin and vancomycin for pediatric CDI treatment.

Keywords:
Clostridium difficilechildrendiarrheapediatric

More Related Videos

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

10.2K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.2K

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
235
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
35
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
622
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
233
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
238